SOPHiA GENETICS (SOPH) CFO’s small 774-share sale covers RSU tax bill

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported a small open-market sale of 774 Ordinary Shares. The shares were sold at a weighted average price of $5.3795 per share on June 22, 2026, and he held 310,684 shares afterward.

According to the disclosure, the sale was made to cover tax withholding obligations from restricted stock units that vested on June 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary.

Insights

Equity compensation analyst

Routine tax-related sale under a 10b5-1 plan with minimal ownership impact.

The transaction shows SOPHiA GENETICS SA CFO George Cardoza sold 774 Ordinary Shares at a weighted average of $5.3795. The filing states this was to satisfy tax withholding from restricted stock units that vested on June 18, 2026.

The footnotes clarify these sales occurred under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. Cardoza’s post-transaction holdings of 310,684 shares indicate the sale is small relative to his position, suggesting a routine, compensation-driven event rather than a directional view on the stock.

Insider Trade Summary 10b5-1

Net Seller: 774 shares ($4,164)

Net Sell 1 txn

Insider CARDOZA GEORGE

Role Chief Financial Officer

Sold 774 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	774	$5.3795	$4K

Holdings After Transaction: Ordinary Shares — 310,684 shares (Direct, null)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 774 shares Weighted average sale price: $5.3795 per share Post-transaction holdings: 310,684 shares +2 more

5 metrics

Shares sold 774 shares Open-market sale on June 22, 2026

Weighted average sale price $5.3795 per share Ordinary Shares sold by CFO

Post-transaction holdings 310,684 shares Direct ownership after sale

Trade price range $5.33–$5.46 per share Multiple transactions included in weighted average

RSU vesting date June 18, 2026 Restricted stock units triggering tax withholding

Key Terms

restricted stock units, Rule 10b5-1(c) trading plan, tax withholding obligations, weighted average price

4 terms

restricted stock units financial

"arising in connection with the vesting of restricted stock units on June 18, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) trading plan regulatory

"These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan"

A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.

tax withholding obligations financial

"sold ... to satisfy tax withholding obligations arising in connection with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARDOZA GEORGE

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/22/2026		S		774(1)	D	$5.3795(2)	310,684	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units on June 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.33 to $5.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-Fact for George Cardoza	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) CFO George Cardoza report in this Form 4?

George Cardoza reported selling 774 Ordinary Shares of SOPHiA GENETICS SA. The shares were sold at a weighted average price of $5.3795, primarily to cover tax withholding obligations tied to recently vested restricted stock units.

At what price did the SOPHiA GENETICS (SOPH) CFO sell shares?

The CFO sold 774 Ordinary Shares at a weighted average price of $5.3795 per share. Footnotes state the trades occurred in multiple transactions with prices ranging from $5.33 to $5.46 per share, all on the same trading date.

How many SOPHiA GENETICS (SOPH) shares does the CFO hold after the sale?

After selling 774 Ordinary Shares, the CFO directly holds 310,684 shares of SOPHiA GENETICS SA. This indicates the reported sale was small relative to his overall position, consistent with a routine tax-related transaction disclosed in the filing.

Why did the SOPHiA GENETICS (SOPH) CFO sell shares according to the filing?

The filing explains the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on June 18, 2026. The sale is described as a tax-related event, not a discretionary decision to reduce the CFO’s investment exposure.

Was the SOPHiA GENETICS (SOPH) CFO’s share sale made under a Rule 10b5-1 plan?

Yes. The footnotes state the sales were effected under a pre-established Rule 10b5-1(c) trading plan. Such plans schedule trades in advance, so the timing of this sale is characterized as non-discretionary rather than an opportunistic market-timing decision.

What trading range did SOPHiA GENETICS (SOPH) shares have for this insider sale?

The filing notes that the reported weighted average price of $5.3795 reflects multiple trades. These occurred at prices between $5.33 and $5.46 per share. The reporting person offers to provide detailed trade breakdowns upon written request.